About Sorting nexin-27
Sorting nexin-27 (SNX27) is a protein
from Homo sapiens identified by UniProt accession
Q96L92, 541 residues long.
MolForge cross-references it against 0 known binders and
123 disease associations.
Target properties
| Protein name | Sorting nexin-27 |
| UniProt accession | Q96L92 |
| Gene | SNX27 |
| Organism | Homo sapiens |
| Length | 541 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (123)
Diseases linked to this target (Open Targets).
- Dravet syndrome · score 0.55
- Global developmental delay · score 0.42
- Intellectual disability · score 0.42
- Generalized hypotonia · score 0.42
- Seizure · score 0.42
- leukocyte count · score 0.22
- neutrophil count · score 0.22
- genetic disorder · score 0.19
- granulocyte count · score 0.17
- Blackfan-Diamond anemia · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96L92-F1 | alphafold | PREDICTED | 83.63 | — |
Amino-acid sequence (541 residues)
MADEDGEGIH PSAPHRNGGG GGGGGSGLHC AGNGGGGGGG PRVVRIVKSE SGYGFNVRGQ VSEGGQLRSI NGELYAPLQH VSAVLPGGAA DRAGVRKGDR ILEVNHVNVE GATHKQVVDL IRAGEKELIL TVLSVPPHEA DNLDPSDDSL GQSFYDYTEK QAVPISVPRY KHVEQNGEKF VVYNVYMAGR QLCSKRYREF AILHQNLKRE FANFTFPRLP GKWPFSLSEQ QLDARRRGLE EYLEKVCSIR VIGESDIMQE FLSESDENYN GVSDVELRVA LPDGTTVTVR VKKNSTTDQV YQAIAAKVGM DSTTVNYFAL FEVISHSFVR KLAPNEFPHK LYIQNYTSAV PGTCLTIRKW LFTTEEEILL NDNDLAVTYF FHQAVDDVKK GYIKAEEKSY QLQKLYEQRK MVMYLNMLRT CEGYNEIIFP HCACDSRRKG HVITAISITH FKLHACTEEG QLENQVIAFE WDEMQRWDTD EEGMAFCFEY ARGEKKPRWV KIFTPYFNYM HECFERVFCE LKWRKENIFQ MARSQQRDVA T
Explore Sorting nexin-27 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets